Business Wire

Proximus harnesses ADVA synchronization solution for 5G network timing

23.3.2021 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Proximus is leveraging its Oscilloquartz timing technology to synchronize Belgium’s largest open mobile network. The deployment enables Proximus to improve speed, coverage and reliability for millions of mobile users throughout Belgium, while also preparing its network for next-generation services. By deploying ADVA’s core grandmaster devices, access boundary clocks and its enhanced primary reference time clock (ePRTC) solution, the country’s incumbent telecommunications service provider is ensuring the levels of timing accuracy and resilience needed for 5G, broadcast and other time-sensitive services. The technology was implemented by ADVA’s partner Arcadiz Telecom, a leading provider of connectivity solutions across the Benelux region.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005060/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s timing technology is an integral part of Proximus’s 5G strategy (Photo: Business Wire)

“By harnessing ADVA’s network timing innovation, we’re ensuring unprecedented levels of precision and reliability. This deployment is a core component of our 5G strategy. It means more value not only for our customers looking to access data-intensive applications and stream high-quality video wherever they are, but also for telco operators using our open network,” said Patrick Delcoigne, director, network engineering and operations, Proximus. “ADVA’s grandmaster clock and ePRC cesium technology empower us to meet key timing challenges. It enables highly accurate phase precision, enhanced stability and long-term protection from GNSS outages. Just as important, though, is the support of the ADVA and Arcadiz Telecom team. Their engineers have worked closely with us to ensure that the network meets all of our requirements.”

Proximus’s new nationwide synchronization network is built on the OSA 5440, an ultra-stable timing solution optimized for deployment in core networks and the OSA 5412 family of cost-effective, mid-scale synchronization devices engineered for deployment in a wide range of locations. It’s anchored by the robust and proven OSA 3230B ePRC cesium clock installed in two central sites. This supports high levels of frequency stability compliant with the strictest ITU-T standards and, combined with the OSA 5440, ensures long-term stability of UTC time. The extended stability performance of ADVA’s ePRC provides immunity against GNSS outages – a crucial requirement for mission-critical applications that should not rely on satellite-based timing alone.

“For major mobile network operators like Proximus, our PTP grandmaster and boundary clocks and our ePRTC solution are the perfect tools. They enhance overall performance and deliver the precision timing necessary for 5G use cases. Our technology also enables other services such as broadcast networks to migrate to IP-based timing,” commented Jörg Urban, senior director, business development, Oscilloquartz, ADVA. “The OSA 5412 Series and OSA 5440 support a smooth and cost-effective migration to next-generation phase and frequency synchronization. And with our ePRTC solution providing robust backup for GNSS, Proximus’ mobile customers can be sure of high-quality, uninterrupted services with no loss of performance.”

“At Arcadiz Telecom, we know what it takes to build a network ready to support tomorrow’s services. With ADVA’s Oscilloquartz timing technology and the ongoing support and maintenance of our team, Proximus can be confident that its synchronization infrastructure delivers for today’s needs while being fully equipped for the future,” said Marc Vandeputte, CTO, Arcadiz Telecom. “When it comes to 5G connectivity, every nanosecond counts. That’s why the stringent accuracy and stability of ADVA’s technology is so important. It empowers Proximus to deliver enhanced speeds, coverage and quality to its mobile users. For Belgians, this deployment will enable a wide range of new experiences from instant access to video streams to immersive AR and VR experiences.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye